FindTrial
Sign In

tTF-NGR

BIOLOGICAL3 trials

Sponsors

Universitaet Muenster, University Hospital Muenster, Universität Münster

Conditions

LymphomasMalignant Solid TumorsPatients (18-75 years) with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing 1st line therapy or with contraindications to anthracyclines (CD13 positivity: grade >/= 1+)Soft Tissue Sarcoma

Phase 1

tTF-NGR Phase I Study
CompletedNCT02902237
University Hospital MuensterLymphomas, Malignant Solid Tumors
Start: 2017-03-01End: 2019-11-05Updated: 2020-12-08

Phase 3

tTF-NGR Randomized Study - STS
RecruitingNCT05597917
Universität MünsterSoft Tissue Sarcoma
Start: 2021-10-26End: 2026-12-31Target: 126Updated: 2025-04-04
Phase III study comparing Trabectedin (T) versus T plus tTF-NGR to entrap T inside the tumor in patients with metastatic and/or refractory soft tissue sarcoma (STS), Acronym: TRABTRAP
RecruitingCTIS2024-516392-33-00
Universitaet MuensterPatients (18-75 years) with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing 1st line therapy or with contraindications to anthracyclines (CD13 positivity: grade >/= 1+)
Start: 2021-09-17Target: 126Updated: 2025-09-04